Axonics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Axonics şirketinin toplam hissedar öz sermayesi $664.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $774.2M ve $109.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$345.23m
Eşitlik	US$664.49m
Toplam yükümlülükler	US$109.68m
Toplam varlıklar	US$774.17m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0I3 'nin kısa vadeli varlıkları ( $525.9M ) kısa vadeli yükümlülüklerini ( $64.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0I3 şirketinin kısa vadeli varlıkları ( $525.9M ) uzun vadeli yükümlülüklerini ( $45.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0I3 borçsuzdur.

Borcun Azaltılması: 0I3 şirketinin 5 yıl önce borç/öz sermaye oranı 21.8% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan 0I3 mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: 0I3 kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 30.7 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Axonics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023)

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings released: EPS: US$0.068 (vs US$0.15 loss in 2Q 2023)

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings released: US$0.38 loss per share (vs US$0.19 loss in 1Q 2023)

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings released: US$0.12 loss per share (vs US$1.28 loss in FY 2022)

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.34 loss in 3Q 2022)

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

New minor risk - Share price stability

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Forecast breakeven date moved forward to 2024

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 2Q 2022)

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.50 loss in 1Q 2022)

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.86 loss in FY 2021)

Forecast to breakeven in 2025

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Now 22% undervalued after recent price drop

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold €127k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.39 loss in 3Q 2021)

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Chief Medical Officer recently sold €751k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.59 loss in 2Q 2021)

Axonics, Inc. Updates Revenue Guidance for the Year of 2022

Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

First quarter 2022 earnings released: US$0.50 loss per share (vs US$0.57 loss in 1Q 2021)

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2022

Axonics, Inc. Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

Axonics, Inc., Annual General Meeting, May 25, 2022

Axonics, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new directors

Chief Medical Officer recently sold €700k worth of stock

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

President & CFO recently sold €788k worth of stock

President & CFO recently sold €788k worth of stock

Axonics, Inc. Provides Earning Guidance for the Fourth Quarter and Fiscal Year of 2021

Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.24 loss in 3Q 2020)

Axonics, Inc. Provides Additional Update on Inter Partes Review Proceedings

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.54 loss in 2Q 2020)

Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Axonics, Inc. Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator

Axonics Receives FDA Approval Further Expanding MRI Labeling

Axonics, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.43 loss in 1Q 2020)

Axonics Provides Revenue Guidance for the Year 2021

Axonics Modulation Technologies, Inc. Announces Strategic Alliance with Micro Systems Technologies for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device

Full year 2020 earnings released: US$1.49 loss per share (vs US$2.80 loss in FY 2019)

Revenue misses expectations